Thomas J. Saphner
Experienced in Sertoli-Leydig Cell Tumor

Dr. Thomas J. Saphner

Hematology | Oncology
5300 Memorial Dr, 
Two Rivers, WI 
On Staff At
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Sertoli-Leydig Cell Tumor
5300 Memorial Dr, 
Two Rivers, WI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Thomas Saphner is a Hematologist and an Oncologist in Two Rivers, Wisconsin. Dr. Saphner is rated as an Experienced provider by MediFind in the treatment of Sertoli-Leydig Cell Tumor. His top areas of expertise are Paget Disease of the Breast, Upper Tract Urothelial Carcinoma (UTUC), Inflammatory Breast Cancer, and Angiosarcoma.

His clinical research consists of co-authoring 19 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years.

Residency
University of Kentucky
Specialties
Hematology
Oncology
Licenses
Internal Medicine in MI
Board Certifications
American Board Of Internal Medicine
Fellowships
University of Wisconsin Hospital and Clinics, Medical Oncology
Hospital Affiliations
Aurora Health Care Central Inc
Aurora Medical Ctr Manitowoc County
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Aspirus Arise Health
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Common Ground Healthcare
  • OTHER COMMERCIAL
Common Ground Healthcare Cooperative
  • EPO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Network Health
  • HMO
Quartz
  • HMO
  • POS
  • PPO
Quartz Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Vince Lombardi Cancer Clinic
5300 Memorial Dr, Two Rivers, WI 54241
Other Locations
Aurora Cancer Care
3003 University Dr, Marinette, WI 54143
Vince Lombardi Cancer Clinic
855 N Westhaven Dr, Oshkosh, WI 54904

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing
Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing
Enrollment Status: Recruiting
Publish Date: September 19, 2025
Intervention Type: Drug, Other, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Enrollment Status: Active_not_recruiting
Publish Date: September 30, 2025
Intervention Type: Drug, Other, Procedure
Study Drugs: Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Ibrutinib, Melphalan
Study Phase: Phase 3
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Drug
Study Drugs: Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 2
NCORP Tissue Procurement Protocol: An NCI Cancer Moonshot Study
NCORP Tissue Procurement Protocol: An NCI Cancer Moonshot Study
Enrollment Status: Active_not_recruiting
Publish Date: September 10, 2025
Intervention Type: Procedure
Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions
Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Behavioral
Study Phase: Phase 3
The National Myelodysplastic Syndromes Natural History Study
The National Myelodysplastic Syndromes Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2025
Intervention Type: Other
EROS: Engendering Reproductive Health Within Oncologic Survivorship
EROS: Engendering Reproductive Health Within Oncologic Survivorship
Enrollment Status: Active_not_recruiting
Publish Date: June 13, 2025
Intervention Type: Other
Study Phase: Not Applicable
Olanzapine With or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial
Olanzapine With or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial
Enrollment Status: Completed
Publish Date: April 06, 2025
Intervention Type: Other, Drug
Study Phase: Phase 3
Implementing a Virtual Tobacco Treatment in Community Oncology Practices: Smoke Free Support Study 2.0
Implementing a Virtual Tobacco Treatment in Community Oncology Practices: Smoke Free Support Study 2.0
Enrollment Status: Completed
Publish Date: March 18, 2025
Intervention Type: Other, Drug
Study Phase: Not Applicable
Longitudinal Assessment of Financial Burden in Patients With Colon or Rectal Cancer Treated With Curative Intent
Longitudinal Assessment of Financial Burden in Patients With Colon or Rectal Cancer Treated With Curative Intent
Enrollment Status: Active_not_recruiting
Publish Date: February 17, 2025
Intervention Type: Other
Understanding and Predicting Breast Cancer Events After Treatment (UPBEAT)
Understanding and Predicting Breast Cancer Events After Treatment (UPBEAT)
Enrollment Status: Active_not_recruiting
Publish Date: November 25, 2024
Intervention Type: Diagnostic test
Study Phase: Not Applicable
Phase II Study of Low-Dose Ibuprofen for Cognitive Problems in Patients With Cancer
Phase II Study of Low-Dose Ibuprofen for Cognitive Problems in Patients With Cancer
Enrollment Status: Completed
Publish Date: September 25, 2023
Intervention Type: Other, Drug
Study Drug: Ibuprofen
Study Phase: Phase 2
A Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil in Chemotherapy Exposed Breast Cancer Survivors With Cognitive Impairment
A Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil in Chemotherapy Exposed Breast Cancer Survivors With Cognitive Impairment
Enrollment Status: Completed
Publish Date: September 13, 2023
Intervention Type: Drug
Study Drug: Donepezil 
Study Phase: Phase 3
View 14 Less Clinical Trials

19 Total Publications

A qualitative examination of cognitive behavioral therapy strategies and health management content to reduce fear of cancer recurrence among breast cancer survivors: Results from the FoRtitude study.
A qualitative examination of cognitive behavioral therapy strategies and health management content to reduce fear of cancer recurrence among breast cancer survivors: Results from the FoRtitude study.
Journal: Journal of health psychology
Published: July 28, 2025
Similar Doctors
Distinguished in Sertoli-Leydig Cell Tumor
Dr. William H. Bradley
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Distinguished in Sertoli-Leydig Cell Tumor
Dr. William H. Bradley
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

The Medical College Of Wisconsin Inc

3200 Pleasant Valley Rd, 
West Bend, WI 
 (29.1 miles away)
262-836-7300
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

William Bradley is a Gynecologic Oncologist and an Oncologist in West Bend, Wisconsin. Dr. Bradley is rated as a Distinguished provider by MediFind in the treatment of Sertoli-Leydig Cell Tumor. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Sertoli-Leydig Cell Tumor, Ovarian Carcinosarcoma, and Hysterectomy. Dr. Bradley is currently accepting new patients.

Elizabeth L. Michelson
Advanced in Sertoli-Leydig Cell Tumor
Dr. Elizabeth L. Michelson
Oncology
Advanced in Sertoli-Leydig Cell Tumor
Dr. Elizabeth L. Michelson
Oncology

Aurora BayCare Gynecologic Oncology

2845 Greenbrier Rd, 
Green Bay, WI 
 (50.6 miles away)
920-288-8208
Languages Spoken:
English
See accepted insurances

Elizabeth Michelson is an Oncologist in Green Bay, Wisconsin. Dr. Michelson is rated as a Distinguished provider by MediFind in the treatment of Sertoli-Leydig Cell Tumor. Her top areas of expertise are Endometrial Cancer, Endometrial Stromal Sarcoma, Malignant Mixed Mullerian Tumor, Vaginectomy, and Ureteroscopy.

Advanced in Sertoli-Leydig Cell Tumor
Dr. Edgard A. Badine
Hematology Oncology | Hematology | Oncology
Advanced in Sertoli-Leydig Cell Tumor
Dr. Edgard A. Badine
Hematology Oncology | Hematology | Oncology

Ascension Ne Wisconsin, Inc

1506 S Oneida St, 
Appleton, WI 
 (41.0 miles away)
920-738-2000
Languages Spoken:
English, Arabic, French, German, Spanish
See accepted insurances
Accepting New Patients

Edgard Badine is a Hematologist Oncology specialist and a Hematologist in Appleton, Wisconsin. Dr. Badine is rated as an Advanced provider by MediFind in the treatment of Sertoli-Leydig Cell Tumor. His top areas of expertise are Pancreatoblastoma, Pleuropulmonary Blastoma, Lung Cancer, Myelodysplastic Syndrome (MDS), and Bone Marrow Aspiration. Dr. Badine is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Saphner's expertise for a condition
ConditionClose
    View All 10 Advanced Conditions
    View All 66 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile